SequelSEC

Krystal Biotech, Inc. KRYS

Biological Products, (No Diagnostic Substances) · CIK 0001711279 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$440.48M
Fiscal year ended 2026-06-30
Operating income
$197.75M
Fiscal year ended 2026-06-30
Free cash flow
$257.78M
Fiscal year ended 2026-06-30

Krystal Biotech, Inc. (KRYS) reported revenue of $440.48M and net income of $241.46M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Krystal Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Krystal Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$440.48M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$197.75M
Net income$241.46M
Research & development$59.23M
Weighted-average diluted sharesUnavailable
Pretax income$226.62M
Income tax expense-$14.85M
Diluted EPSUnavailable
Selling, general & administrative$159.89M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Krystal Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$427.74M
Total assets$1.50B
Current assets$1.06B
Total liabilities$141.52M
Current liabilities$127.40M
Total equity incl. NCI$1.36B
Temporary (mezzanine) equityUnavailable
Inventory$45.56M
Accounts receivable$138.66M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$6.54M

Cash flow

Krystal Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$272.34M
Capital expenditures$14.56M
Investing cash flow-$218.29M
Financing cash flow$23.97M
Net change in cash$73.91M
Stock-based compensation$54.68M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Krystal Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$257.78M
Gross marginUnavailable
Operating margin44.9%
FCF margin58.5%
SBC / revenue12.4%
Current ratio8.32x
Revenue YoY growth22.6%
Net margin54.8%
R&D / revenue13.4%
CapEx / revenue3.3%
Long-term debt / equityUnavailable
Effective tax rate-6.6%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KRYS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.